

FY25 Result Presentation

27 August 2025

A background image showing two medical professionals, a man and a woman, both wearing white lab coats. They are looking down at a tablet computer held by the man. The image is overlaid with a dark blue semi-transparent filter. Green L-shaped decorative lines are present: one in the top right corner and another in the bottom left corner.

Mach7 Technologies delivers
advanced data management
and diagnostic viewing solutions
to healthcare organisations
worldwide.

Agenda

1 Business Overview

2 FY25 Results

3 Outlook



Teri Thomas | CEO



Dyan O'Herne | CFO

Business Overview

Positioning Mach7 for sustainable long-term profitable growth



1. Changes to the leadership team since 1 July 2025 include the appointments of Managing Director and CEO, Teri Thomas and Mach7's first Chief Innovation Officer, Paul Jensen, as well as the departures of David Madaffri, Chief Operating Officer and Lisa Thompson, Vice President, Services. On 19 August 2025, Mach7 announced that the Chief Financial Officer Dyan O'Herne will step down from the role on 30 September 2025.

Strategic Priorities



Review market positioning and shift to customer value-centric growth strategy



Define & target ideal customer profiles (ICP)

Ensure product roadmap, marketing and positioning align with ICPs to drive sales effectiveness and new logo acquisition.



Transform customer facing operations

New *Flight Crew* structure with each customer supported by designated ACE.¹ Deliver measurable improvements in customer satisfaction and higher KLAS scores.



Deliver customer compelling innovations

New Chief Innovation Officer and strengthened R&D team positioned to accelerate delivery of innovative solutions, leveraging AI tools.



1. Advocate for Customer Experience (ACE) who coordinates multi-disciplinary team.

Transforming our customer engagement

Flight Crew - revitalising how Mach7 serves its customers and partners



One multi-disciplinary customer designated team



Led by Advocate for Customer Experience (ACE)



Clear accountability improves support response time




Delivers consistent Mach7 experience



Stronger relationships provides greater continuity



Drives *Mach7 Loop*



The Mach7 Loop

Our cycle of compounding growth



FY25 Results

FY25 in Review

Strong foundation in place for driving future growth

- ① Delivered solid growth in revenue, CARR and ARR.


- ② Demonstrated cost discipline across the year and met guidance for OPEX growth to be less than FY25 revenue growth.

- ③ Delivered significant profit improvement which drove operating leverage and progress towards recurring revenue covering OPEX.

- ④ Met objective of being operating cash flow positive in FY25.

- ⑤ Strong financial position with no debt.

- ⑥ Initiated on-market share buy-back program in H2 FY25 with 6.3M shares acquired (A\$2.2M).



FY25 Financial Highlights



A\$33.8M

Revenue

+A\$4.7M or +16% on PCP¹
In line with FY25
Guidance²

A\$25.3M

Recurring Revenue³

+A\$4.3M or +20% on PCP
75% of total revenue
(FY24: 72%)
80% of OPEX (FY24: 72%)

A\$30.2M

CARR⁴

+A\$2.3M or +8% on PCP
In line with updated
FY25 Guidance²

A\$23.5M

ARR⁵ Run Rate

+A\$1.5M or +7% on PCP

A\$31.8M

Operating Expenses

+A\$2.5M or +9% on PCP
In line with FY25 Guidance²

-A\$0.3M

EBITDA (adjusted)⁶

(PCP: -A\$2.0M)

A\$0.4M

NPATA⁷

(PCP: -A\$1.2M)

NPAT -A\$6.2M

(PCP: -A\$8.0M)

A\$23.1M

Closing Cash⁸

(PCP: A\$26.2M)

Positive Operating Cash flow
Strong financial position,
no debt


1. PCP – Prior Corresponding Period; 2. In August 2024, Mach7 provided FY25 guidance for 15-25% growth in CARR and revenue on PCP and for OPEX growth to be less than revenue growth. This was updated on 10 July 2025 with CARR growth expected to finalise at A\$30M-31M, slightly below 15-25% growth, revenue of A\$33M-34M was expected to finalise at the low end of prior guidance. Mach7 reaffirmed guidance for OPEX growth to be less than revenue growth. 3. Recurring revenue consists of Subscription revenue and Maintenance and Support revenue recognised; 4. CARR: Contracted Annual Recurring Revenue; 5. Annual Recurring Revenue (ARR) is revenue earned from Subscription and Maintenance and Support fees at the end of June, annualised; 6. EBITDA adjusted for net unrealised foreign exchange movements and non-cash share-based payments expense; 7. NPATA: (Net Profit After Tax and before Amortisation) is NPAT adjusted for amortisation of acquired intangibles; 8. A\$2.2M used in H2 FY25 to buy back 6.3M shares as part of on-market share buy-back program.

16% Revenue Growth on PCP

Recurring revenue up 20% on PCP

- **Revenue** of A\$33.8M, up 16% on PCP (FY24: A\$29.1M). In line with FY25 guidance.
- **Recurring Revenue** of A\$25.3M, up 20% on PCP, accounting for 75% of total revenue (FY24: 72%) and representing 80% of OPEX (FY24: 72%).
- **Professional Services Revenue** of A\$3.7M, down 10% and represented 11% of total revenue (FY24: A\$4.1M; 14% of total revenue).
- **Capital Licence Revenue** of A\$4.8M up 21% on PCP due to add-on and expansion orders from existing customers (14% of total revenue). (FY24: A\$4.0M; 14% of total revenue).¹
- **Product revenue** split similar to FY24 at approximately 60/40 between VNA and Viewer.

High quality recurring revenue covers 80% OPEX



	FY25	FY24	% Change
Enterprise Diagnostic Viewer (eUnity)	14.3	12.4	15%
Enterprise Data Management (VNA) ²	19.5	16.7	17%
Total	33.8	29.1	16%

1. Mach7 will continue to have some component of capital licences especially for customers in the APAC region
2. Includes departmental workflow applications

Foundational book of business



Strong growth in expansions and add-ons highlights increased usage by existing customers

- **Sales orders** of A\$29.1M (TCV¹) compared to A\$61.3M in FY24 which was a record year for Mach7 with a large renewal program representing 61% of sales orders (A\$38M).
- **Annual Recurring Revenue (ARR)-type Sales of A\$20.4M** (70% of sales orders) representing Subscription and Maintenance and Support Fees. Recognised as revenue when customer achieves FPU² or from date of renewal (FY24: A\$50.9M, 83% of sales orders due to shift to Subscription sales and large renewal program).
- **Capital Software Sales of A\$4.7M** (16% of sales orders) primarily for existing customer add-on and expansion orders (FY24: A\$3.9M, 6% of sales orders).
- **Professional Services Sales of A\$4.0M** (14% of sales orders) decreased compared to PCP (FY24: A\$6.5M, 11% of sales orders).



1. TCV – Total Contract Value comprising capital software licence fees, professional service fees, annual Subscription fees + annual Maintenance and Support fees over contract life; 2. First Productive Use (FPU).

Strong revenue growth and cost discipline drive EBITDA improvement



Achieved objective of being operating cash flow positive in FY25

- **OPEX growth of 9%** in line with FY25 guidance for OPEX growth to be less than revenue growth. Cost discipline demonstrated across the year with H2 FY25 OPEX growth of 3% on PCP.
- **EBITDA (adjusted)** of -A\$0.3M showing significant improvement over PCP (FY24: -A\$2.0M).
- **NPATA of A\$0.4M and NPAT of -A\$6.2M** improved due to strong revenue growth and tight cost control.
- **Cash Receipts** from customers increased by 2% to A\$35.7M due to timing of contract milestones and ARR renewals.
- **Operating Cash flow** of A\$0.9M with Mach7 meeting its operating cash flow positive objective and delivering 3 consecutive positive quarters.
- **A\$23.1M cash** at 30 June 2025 and no debt. Mach7 commenced an on-market share buy-back on 3 March 2025, acquiring 6.3M shares and utilising A\$2.2M for the share buy-back program in FY25.

Earnings (A\$M) ¹	FY25	FY24	\$ Change	% Change
Revenue	33.8M	29.1M	4.7M	16%
Cost of sales	(2.0M)	(1.4M)	(0.6M)	38%
Gross Margins %	94%	95%	-90bps	-
Operating Expenses	(31.8M)	(29.3M)	(2.5M)	9%
EBITDA	(1.5M)	(3.3M)	1.9M	(56%)
EBITDA (adjusted) ²	(0.3M)	(2.0M)	1.7M	(86%)
NPATA ³	0.4M	(1.2M)	1.6M	(135%)
NPAT	(6.2M)	(8.0M)	1.8M	(22%)

Cashflow (A\$M) ¹	FY25	FY24	\$ Change	% Change
Cash Receipts	35.7M	34.9M	0.8M	2%
Net Operating CF	0.9M	3.5M	(2.6M)	(75%)
Closing Cash Balance	23.1M	26.2M	(3.1M)	(12%)

1. Note there may be some minor differences due to rounding

2. EBITDA adjusted for net unrealised foreign exchange movements and non-cash share-based payments expense

3. NPATA: (Net Profit After Tax and before Amortisation) is NPAT adjusted for amortisation of acquired intangibles

Outlook

Outlook



- As demand for imaging continues to grow in both diagnostic frequency and clinical importance, Mach7 is well placed as a partner of choice for providers worldwide.
- New customer engagement model designed to drive improvements in customer satisfaction and the *Mach7 Loop*.
- Mach7 will leverage team strengths across its core markets to enhance customer and technical support and R&D capacity in a cost-effective manner.
- Investment in sales with continued focus on subscription sales in North America to drive high quality, recurring revenue.
- Mach7 is undertaking a comprehensive strategic review with details of the new strategy to be released in Q2 FY26.
- While it remains on foot, Mach7 will pause activity in the on-market share buy-back program pending completion of its strategic review.
- FY26 guidance will be provided when the new growth strategy is released in Q2 FY26.

Contact Us

Investor Relations, Mach7

Françoise Dixon
+61 (0) 412 292 977
ir@mach7t.com

Registered Office: Suite 2, Level 11, 385 Bourke St,
Melbourne, VIC 3000

This document was authorised for release to the
ASX by Teri Thomas, Managing Director and Chief
Executive Officer

Mach7 Technologies

Disclaimer

“Forward looking” statements



Summary of information: This presentation contains general and background information about Mach7 Technologies Limited (“M7T”) activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision. This presentation is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or under any other law. The presentation does not purport to contain all the information that a prospective investor may require in assessing a possible investment in M7T nor does it contain all the information which would be required in a prospectus prepared in accordance with the requirements of the Corporations Act 2001 (Cth). The information provided is in summary form, has not been independently verified, and should not be considered to be comprehensive or complete. It should be read solely in conjunction with the oral briefing provided by M7T and all other documents provided to you by M7T. The information in this presentation remains subject to change without notice. M7T is not responsible for providing updated information and assumes no responsibility to do so.

Not financial product advice: This financial information provided in this presentation is for information purposes only. The information contained in this presentation is of a general nature only and is not a financial product, investment advice or a recommendation to acquire M7T securities and has been prepared without taking into account the objectives, financial situation or needs of any person or entity. Before making an investment decision prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. M7T is not licensed to provide financial product advice in respect of its securities or and other financial products. Cooling off rights do not apply to the acquisition of M7T securities. M7T assumes that the recipient is capable of making its own independent assessment, without reliance on this document, of the information and potential investment and will conduct its own investigation.

Disclaimer: M7T and its related bodies corporate and each of their respective directors, agents, officers, employees and advisors expressly disclaim, to the maximum extent permitted by the law, all abilities (however, caused, including negligence) in respect of, make no representations regarding, and take no responsibility for, any part of this presentation and make no representation or warranty as to the currency, accuracy, reliability or completeness of any information, statements, opinions, conclusions or representations contained in this presentation. In particular, this presentation does not constitute, and shall not be relied upon as, a promise, representation, warranty or guarantee as to the past, present or future performance of M7T.

Future performance: This presentation contains certain forward-looking statements and opinions. The forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forward-looking statements, including projections, forecasts and estimates, are provided as a general guide only and should not be relied on as an indication or guarantee of future performance and involve known and unknown risks, uncertainties and other factors, many of which are outside the control of M7T. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast.

Risks: An investment in M7T securities is subject to investment and other known and unknown risks, some of which are beyond the control of M7T. You should have regard to the ‘Key Risks’ section of this presentation which outlines some of these risks.

Not an offer: This presentation is not, and should not be considered as, an offer or an invitation to acquire securities in M7T or any other financial products and neither this document nor any of its contents will form the basis of any contract or commitment. This presentation is not a prospectus. Offers of securities in M7T will only be made in places which, or to persons to whom it would be lawful to make such offers. This presentation must not be disclosed to any other party and does not carry any right of publication. Neither this presentation nor any of its contents may be reproduced or used for any other purpose without the prior written consent of M7T.

No distribution in the US: This presentation is not an offer of securities for sale in the United States. Any securities to be issued by M7T have not been and will not be registered under the US Securities Act of 1933, as amended (the “US Securities Act”) and may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act. No public offer of the securities is being made in the United States and the information contained herein does not constitute an offer of securities for sale in the United States. This presentation is not for distribution directly or indirectly in or into the United States or to US persons.

Monetary values: Unless otherwise stated, all dollar values are in Australian dollars (AUD\$). The information in this presentation remains subject to change without notice.

Sophisticated and professional investor: By attending this presentation, you present and warrant that (i) if you are in Australia, you are a person to whom an offer of securities may be made without a disclosure document as defined in the Corporation Act 2001 (Cth) (“Corporation Act”) on the basis that you are exempt from the disclosure requirements of Part 6D.2 in accordance with Section 708(8) or 708(11) of the Corporations Act; (ii) if you are in the United States, you are a qualified institutional buyer (as defined under Rule 144A Under the U.S. Securities Act; (iii) if you are outside Australia and the United States, you are a person to whom an offer and issue of securities can be made outside Australia without registration, lodgement or approval of a formal disclosure document or other filing in accordance with the laws of that foreign jurisdiction. If you are not such a person, you are not entitled to attend this presentation. Please return this presentation and any copies and do not provide this presentation to any other person.

No distribution: Distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable security laws.